<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35091101</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">1530-891X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>28</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists</Title>
          <ISOAbbreviation>Endocr Pract</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Performance of Thyroid-Stimulating Immunoglobulin Bioassay and Thyrotropin-Binding Inhibitory Immunoglobulin Assay for the Diagnosis of Graves' Disease in Patients With Active Thyrotoxicosis.</ArticleTitle>
        <Pagination>
          <StartPage>502</StartPage>
          <EndPage>508</EndPage>
          <MedlinePgn>502-508</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eprac.2022.01.007</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1530-891X(22)00026-X</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Graves' disease (GD) is caused by the stimulation of thyrotropin receptors by autoantibodies. We compared the diagnostic accuracy of the thyroid-stimulating immunoglobulin (TSI) bioassay and thyrotropin-binding inhibitory immunoglobulin (TBII) assay in differentiating GD from other causes of thyrotoxicosis.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively evaluated 493 patients with thyrotoxicosis who were tested with the third-generation TSI and TBII assays simultaneously. Patients were classified according to the clinical, histopathologic, and imaging criteria into the following groups: positive reference group (PRG) (patients with GD), negative reference group (NRG) (patients without GD), and inconclusive group (patients without a definitive diagnosis).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">TSI and TBII assays were concordant in 88% of the cases and showed a strong positive correlation (r<sub>s</sub> = 0.844, P &lt; .01). When analyzed collectively, TSI and TBII assays confirmed the diagnosis of GD in 79% of the PRG cases and excluded GD in 92.5% of patients in NRG. Combined TSI and TBII assays or TBII assay alone showed similar accuracy to the diagnosis of GD (81.4% and 77.5%, respectively). Tests in 40 of 191 patients in PRG were negative for both TSI and TBII assays, whereas 3 of 40 cases in NRG had at least 1 positive thyrotropin receptor antibody test. False-negative cases were associated with subclinical hyperthyroidism, normal radionuclide uptake, longer duration of thyrotoxicosis, and absence of goiter or Graves' ophthalmopathy.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TSI and TBII assays showed similar performance in differentiating GD from other causes of thyrotoxicosis in a real-world sample of patients with active thyrotoxicosis. In combination, both tests showed little benefit compared with the TBII assay alone. Thyrotropin receptor antibody assay results should be carefully interpreted in patients with mild GD or longstanding disease.</AbstractText>
          <CopyrightInformation>Copyright © 2022 AACE. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Silva de Morais</LastName>
            <ForeName>Nathalie</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Thyroid Section, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: nathalieaos@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Angell</LastName>
            <ForeName>Trevor E</ForeName>
            <Initials>TE</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology and Diabetes, Keck School of Medicine of the University of Southern California, Los Angeles, California.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ahmadi</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Thyroid Section, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alexander</LastName>
            <ForeName>Erik K</ForeName>
            <Initials>EK</Initials>
            <AffiliationInfo>
              <Affiliation>Thyroid Section, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dos Santos Teixeira</LastName>
            <ForeName>Patricia de Fátima</ForeName>
            <Initials>PF</Initials>
            <AffiliationInfo>
              <Affiliation>Endocrinology Service, Hospital Universitário Clementino Fraga Filho and Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marqusee</LastName>
            <ForeName>Ellen</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Thyroid Section, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>01</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Endocr Pract</MedlineTA>
        <NlmUniqueID>9607439</NlmUniqueID>
        <ISSNLinking>1530-891X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018828">Immunoglobulins, Thyroid-Stimulating</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011989">Receptors, Thyrotropin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C094372">thyrotropin-binding inhibitory immunoglobulin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9002-71-5</RegistryNumber>
          <NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001681" MajorTopicYN="N">Biological Assay</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006111" MajorTopicYN="Y">Graves Disease</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049970" MajorTopicYN="Y">Graves Ophthalmopathy</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018828" MajorTopicYN="N">Immunoglobulins, Thyroid-Stimulating</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011989" MajorTopicYN="N">Receptors, Thyrotropin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013971" MajorTopicYN="Y">Thyrotoxicosis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Graves' disease</Keyword>
        <Keyword MajorTopicYN="N">TRAb</Keyword>
        <Keyword MajorTopicYN="N">bioassay</Keyword>
        <Keyword MajorTopicYN="N">diagnosis</Keyword>
        <Keyword MajorTopicYN="N">thyroid-stimulating immunoglobulin</Keyword>
        <Keyword MajorTopicYN="N">thyrotoxicosis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>29</Day>
          <Hour>5</Hour>
          <Minute>35</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35091101</ArticleId>
        <ArticleId IdType="doi">10.1016/j.eprac.2022.01.007</ArticleId>
        <ArticleId IdType="pii">S1530-891X(22)00026-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
